Sign In
Buy ELOX
$12.05
+0.300 (+2.55%)
At Close: Jun 26, 2026
Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
09:00am, Thursday, 07'th Sep 2023
Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
08:30am, Monday, 14'th Aug 2023
Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscop
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
08:00am, Monday, 14'th Aug 2023
All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating th
WATERTOWN, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received
This Small Cap Stock Surged Over 100%
10:52am, Wednesday, 12'th Jul 2023
Arguably the most impressive mover yesterday was a stock you have probably never heard of. Shares of Eloxx Pharmaceuticals NASDAQ: ELOX rocketed almost 100% yesterday after receiving an increased pric
Penny Stocks to Watch: Why Is ELOX Stock Skyrocketing?
03:06pm, Tuesday, 11'th Jul 2023
Most traders dream of hitting it big, and penny stocks are some of the most attractive for day traders. It can be any given session where we see at least a handful of cheap stocks under $5 explode.
Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Com
Why Is Eloxx Pharmaceuticals (ELOX) Stock Down 27% Today?
08:49am, Tuesday, 16'th May 2023
Eloxx Pharmaceuticals (NASDAQ: ELOX ) stock is falling hard on Tuesday after the company provided a weak earnings report for Q1 2023. The bad news for ELOX stock starts with its losses per share of $2
Senesco Technologies Inc. (ELOX) Reports Q1 Loss, Lags Revenue Estimates
06:59pm, Monday, 15'th May 2023
Senesco Technologies Inc. (ELOX) came out with a quarterly loss of $2.88 per share versus the Zacks Consensus Estimate of a loss of $2.55. This compares to loss of $5.20 per share a year ago.
Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
04:10pm, Monday, 06'th Mar 2023
WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it will pr
5 Hot Penny Stocks Exploding After News This Week
09:39am, Thursday, 05'th Jan 2023
Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal
12:48pm, Friday, 16'th Sep 2022
Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.
Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome
08:15pm, Wednesday, 30'th Mar 2022 GlobeNewswire Inc.
Strong rationale for development for Alport syndrome as ELOX-02 has demonstrated significant readthrough in COL4A5 nonsense mutations in preclinical studies and is preferentially transported to kidney
Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation
11:00am, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million for the ongoing ELX-02 clinical program
